A Phase 2 interventional study of SNDX-6352 and Placebo in Coronavirus, COVID and ARDS, sponsored by Syndax Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Syndax Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in Coronavirus Infections with a site in United States — 30 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.
Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 260th largest by enrollment of the 283 interventional ones that give a count, is one of 252 that started in 2020, is one of 90 in phase 2, and was the 171st registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.
Browse Coronavirus Infections studies →30 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Kara Chew · Sites in United States
Ages 40–64 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 122 · Phase 3 70 · Phase 4 21
First in 2003; this study’s year is marked. 252 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 120 across 655 interventional studies indexed under Coronavirus Infections.
Median enrollment 94 across the 283 interventional studies, 428 across the 112 observational. Of the 313 that completed or were terminated, 171 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 401 have an industry lead sponsor. The 10 most frequent:
Syndax Pharmaceuticals is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Syndax Pharmaceuticals has 1 study filed under Coronavirus Infections — fewer than ten, so there is no comparison to draw.
20 of the studies in Coronavirus Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 20 to your calendar (.ics) → With an account.
Among the 401 studies in Coronavirus Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
Axatilimab (SNDX-6352) is a humanized immunoglobin G4 monoclonal antibody with high affinity against colony stimulating factor-1 receptor (CSF-1R) under investigation for the prevention or treatment of respiratory signs and symptoms secondary to COVID-19.
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab as an add-on to SOC therapy in hospitalized participants with respiratory signs and symptoms secondary to COVID-19 compared to SOC treatment.
Eligible participants were to be randomized in a 1:1 ratio to 1 of 2 treatment groups, active or control. All participants were to receive axatilimab or matching placebo intravenously (IV) as an add-on to SOC on Day 1, within 8 hours of randomization and on Day 15. Participants were to be followed for at least 28 days (+3 days) after the first dose of study intervention (Day 29).
The primary objective of the study was to assess the proportion of participants alive and free of respiratory failure at Day 29.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type of Participant and Disease Characteristics -
Illness of any duration with at least 1 of the following:
Radiographic evidence (chest x-ray or computed tomography scan) of 1 of the following:
If the participant was intubated, must have been intubated less than 24 hours prior to randomization
Sex and Guidelines -
Contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
-
Exclusion Criteria:
Medical Conditions -
Female participants who were pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study intervention
Excluded Prior/Concomitant Therapy -
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Axatilimab on Days 1 and 15, IV + SOC
Drug: SNDX-6352
Matching placebo on Days 1 and 15, IV + SOC
Drug: Placebo
SNDX-6352
Also known as: Axatilimab
Placebo comparator
Count Of Participants Alive And Free Of Respiratory Failure At Day 29
Respiratory failure was defined by need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation \>6 liters oxygen/minute, or clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making was driven solely by resource limitation.
Time frame: Day 29
Count Of Participants With Secondary Clinical Improvement Outcomes At Day 29
Participants achieving a ≥2 category improvement on a 7-point ordinal score relative to the baseline on Day 28 as collected on Day 29 are reported.
Time frame: Day 29
Time To Clinical Improvement
The time to clinical improvement is defined as a national early warning score of ≤2 maintained for 24 hours.
Time frame: Baseline through Day29
Change From Baseline At Day 29 In Oxygenation In Hospitalized Adults With Respiratory Signs And Symptoms Secondary To COVID-19 Treated With Axatilimab
The change from baseline at Day 29 or hospital discharge or death, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen is evaluated.
Time frame: Baseline, Day 29
Change From Baseline At Day 15 In Biomarkers Following Treatment With Axatilimab
The change from baseline at Day 15 in serum concentrations of interleukin 6 and c-reactive protein or hospital discharge or death is evaluated.
Time frame: Baseline, Day 15
Count Of Participants Experiencing Adverse Events And Serious Adverse Events
This outcome measure evaluates the safety and tolerability of axatilimab within the same population. A summary of all serious adverse events and other adverse events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
Time frame: Baseline through Day 29
Count Of Participants Requiring Ventilation Support
Participants who required initiation of mechanical ventilation after study entry are analyzed.
Time frame: Baseline through Day 29
Count Of Participants Considered Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Free By Day 15
This outcome measure evaluates the antiviral effects of axatilimab in hospitalized adults by Day 15 or hospital discharge, whichever was sooner, with recently diagnosed SARS-CoV-2 infection.
Time frame: Day 15
Pharmacokinetics: Serum Concentration Of Axatilimab And Anti-drug Antibodies
The serum concentration of axatilimab and presence of anti-drug antibodies is evaluated.
Time frame: Day 29
| Milestone | Axatilimab (SNDX-6352) | Placebo |
|---|---|---|
| Started | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 0 | 0 |
Respiratory failure was defined by need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation \>6 liters oxygen/minute, or clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making was driven solely by resource limitation.
No measurements were reported for this outcome.
Participants achieving a ≥2 category improvement on a 7-point ordinal score relative to the baseline on Day 28 as collected on Day 29 are reported.
No measurements were reported for this outcome.
The time to clinical improvement is defined as a national early warning score of ≤2 maintained for 24 hours.
No measurements were reported for this outcome.
The change from baseline at Day 29 or hospital discharge or death, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen is evaluated.
No measurements were reported for this outcome.
The change from baseline at Day 15 in serum concentrations of interleukin 6 and c-reactive protein or hospital discharge or death is evaluated.
No measurements were reported for this outcome.
This outcome measure evaluates the safety and tolerability of axatilimab within the same population. A summary of all serious adverse events and other adverse events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
No measurements were reported for this outcome.
Participants who required initiation of mechanical ventilation after study entry are analyzed.
No measurements were reported for this outcome.
This outcome measure evaluates the antiviral effects of axatilimab in hospitalized adults by Day 15 or hospital discharge, whichever was sooner, with recently diagnosed SARS-CoV-2 infection.
No measurements were reported for this outcome.
The serum concentration of axatilimab and presence of anti-drug antibodies is evaluated.
No measurements were reported for this outcome.
Collected over This study was terminated by the Sponsor. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axatilimab (SNDX-6352) | — | — | — |
| Placebo | — | — | — |
This study was terminated by the Sponsor. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.
| Age, Continuous | Axatilimab (SNDX-6352) | Placebo | Total |
|---|
| Sex: Female, Male | Axatilimab (SNDX-6352) | Placebo | Total |
|---|---|---|---|
| Female | — | — | — |
| Male | — | — | — |
| Ethnicity (NIH/OMB) | Axatilimab (SNDX-6352) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | — | — | — |
| Not Hispanic or Latino | — | — | — |
| Unknown or Not Reported | — | — | — |
| Race (NIH/OMB) | Axatilimab (SNDX-6352) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | — | — | — |
| Asian | — | — | — |
| Native Hawaiian or Other Pacific Islander | — | — | — |
| Black or African American | — | — | — |
| White | — | — | — |
| More than one race | — | — | — |
| Unknown or Not Reported | — | — | — |
| Region of Enrollment(participants) | Axatilimab (SNDX-6352) | Placebo | Total |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Jul 2020, 1 month.
Results were first posted in Jul 2022, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axatilimab